Literature DB >> 9389704

Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia.

D Grimwade1, P Gorman, E Duprez, K Howe, S Langabeer, F Oliver, H Walker, D Culligan, J Waters, M Pomfret, A Goldstone, A Burnett, P Freemont, D Sheer, E Solomon.   

Abstract

Acute promyelocytic leukemia (APL) is typified by the reciprocal translocation, t(15; 17)(q22; q21), leading to the formation of PML-RARalpha and RARalpha-PML fusion genes. We have characterized 7 cases of morphologic APL found to lack the t(15; 17) on conventional cytogenetic assessment. In 6 of 7 cases, cryptic PML-RARalpha rearrangements were identified by reverse transcriptase-polymerase chain reaction and fluorescent in situ hybridization (FISH); whereas, in the remaining patient, APL was associated with the variant translocation, t(11; 17)(q23; q12-21), leading to the formation of PLZF-RARalpha and RARalpha-PLZF fusion genes. In each of the cases with cryptic PML-RARalpha rearrangements, PML-RARalpha transcripts were detected in the absence of RARalpha-PML, consistent with the concept that PML-RARalpha is the critical oncogenic fusion protein. In 4 of these cases with evaluable metaphase spreads, the occurrence of a nonreciprocal translocation was confirmed by FISH with sole formation of the PML-RARalpha fusion gene; in 3 cases with morphologically normal chromosomes 15 and 17, RARalpha was inserted into PML on 15q, whereas in the remaining patient the PML-RARalpha fusion arose due to insertion of 15q-derived material including PML into RARalpha on 17q. Immunofluorescence studies were performed using antibodies raised against PML and PIC 1, a ubiquitin-homology domain protein previously identified as an interaction partner of PML. In acute myeloid leukemia (AML) of subtypes other than M3, PIC 1 was localized to the nuclear membrane and colocalized with PML within discrete nuclear bodies. In APL cases with cryptic PML-RARalpha rearrangements, the characteristic microparticulate pattern of PML staining was detected with partial colocalization with PIC 1, indicative of disruption of the nuclear bodies; whereas in t(11; 17)-associated APL, PML and PIC 1 remained colocalized within discrete nuclear bodies, as observed in non-APL cases. Although deregulation of the putative growth suppressor PML and delocalization of other nuclear body constituents have been advocated to play a key role in the development of t(15; 17)-associated APL, the present study shows that disruption of PML nuclear bodies per se is not a prerequisite for the pathogenesis of APL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389704

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  The role of fluorescence in situ hybridization technologies in molecular diagnostics and disease management.

Authors:  W King; J Proffitt; L Morrison; J Piper; D Lane; S Seelig
Journal:  Mol Diagn       Date:  2000-12

Review 2.  [Optimized RT-PCR based detection of specific genetic abnormalities within malignant hematopoietic disorders].

Authors:  S Gattenlöhner; M Bonengel; H K Müller-Hermelink
Journal:  Pathologe       Date:  2006-05       Impact factor: 1.011

3.  An efficient and robust statistical modeling approach to discover differentially expressed genes using genomic expression profiles.

Authors:  J G Thomas; J M Olson; S J Tapscott; L P Zhao
Journal:  Genome Res       Date:  2001-07       Impact factor: 9.043

Review 4.  Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies.

Authors:  M Hodges; C Tissot; K Howe; D Grimwade; P S Freemont
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

5.  A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia.

Authors:  J L Pollock; P Westervelt; A K Kurichety; P G Pelicci; J L Grisolano; T J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

6.  A case of a novel PML/RARA short fusion transcript with truncated transcription variant 2 of the RARA gene.

Authors:  Ivana Jezísková; Filip Rázga; Jana Gazdová; Michael Doubek; Tomás Jurcek; Zdenek Korístek; Jirí Mayer; Dana Dvoráková
Journal:  Mol Diagn Ther       Date:  2010-04-01       Impact factor: 4.074

7.  Microgranular variant of acute promyelocytic leukemia with der(17) ins(17;15): A case report and review of the literature.

Authors:  Hongzai Guan; Jing Liu; Xiaofang Guo; Chunmei Wu; Huawei Yu
Journal:  Exp Ther Med       Date:  2015-06-18       Impact factor: 2.447

Review 8.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Susan P Whitman; Clara D Bloomfield
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

9.  Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

Authors:  John S Welch; Peter Westervelt; Li Ding; David E Larson; Jeffery M Klco; Shashikant Kulkarni; John Wallis; Ken Chen; Jacqueline E Payton; Robert S Fulton; Joelle Veizer; Heather Schmidt; Tammi L Vickery; Sharon Heath; Mark A Watson; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Timothy J Ley; Richard K Wilson
Journal:  JAMA       Date:  2011-04-20       Impact factor: 56.272

Review 10.  Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.

Authors:  Yuting Tang; Ying Wang; Liang Hu; Fankai Meng; Danmei Xu; Kai Wan; Lifang Huang; Chunrui Li; Jianfeng Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.